

# Yu Akahoshi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/873620/publications.pdf>

Version: 2024-02-01

84  
papers

764  
citations

687220

13  
h-index

713332

21  
g-index

87  
all docs

87  
docs citations

87  
times ranked

1342  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 574-584.	2.5	6
2	Neutropenia in the First Cycle of Consolidation Chemotherapy with High-Dose Cytarabine Is Not Associated with the Incidence of Relapse in Adult Acute Myeloid Leukemia Patients in First Complete Remission. <i>Acta Haematologica</i> , 2022, 145, 404-411.	0.7	1
3	Prognostic impact of chromosomal changes at relapse after allogeneic hematopoietic cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0
4	Risk factors and outcomes of definite or clinical idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, , 1-9.	0.6	0
5	Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, , 1.	0.7	1
6	Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades. <i>Blood Advances</i> , 2022, 6, 4558-4569.	2.5	5
7	Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality. <i>Clinical Infectious Diseases</i> , 2021, 73, e620-e628.	2.9	16
8	Association of the areas over and under the lymphocyte curve with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2021, 23, e13460.	0.7	3
9	Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2. <i>Blood Advances</i> , 2021, 5, 584-592.	2.5	7
10	Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2021, 113, 832-839.	0.7	9
11	Body Weight Loss Before Allogeneic Hematopoietic Stem Cell Transplantation Predicts Survival Outcomes in Acute Leukemia Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 340.e1-340.e6.	0.6	6
12	Immunity and Vaccination Against Measles, Mumps, and Rubella in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 436.e1-436.e8.	0.6	4
13	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. <i>Clinical Cancer Research</i> , 2021, 27, 4825-4835.	3.2	14
14	Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation—a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2842-2848.	1.3	2
15	Prediction of Cytomegalovirus Reactivation by Recipient Cytomegalovirus-IgG Titer before Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 683.e1-683.e7.	0.6	6
16	Chronic liver graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients during tapering or after stopping calcineurin inhibitors. <i>International Journal of Hematology</i> , 2021, 114, 674-681.	0.7	2
17	Association between the kinetics of cytomegalovirus reactivation in terms of the area under the curve of cytomegalovirus antigenemia and non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2021, 23, e13715.	0.7	2
18	Features of repertoire diversity and gene expression in human cytotoxic T cells following allogeneic hematopoietic cell transplantation. <i>Communications Biology</i> , 2021, 4, 1177.	2.0	3

#	ARTICLE	IF	CITATIONS
19	Surgical resection for persistent localized pulmonary fungal infection prior to allogeneic hematopoietic stem cell transplantation: Analysis of six cases. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 175-180.	0.8	3
20	Skewed Repertoire Reconstitution and Gene Expression of HLA-A2402 CMV-CTLs after Allogeneic HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S321-S322.	2.0	1
21	Effect of Smoking on Outcomes of Allogeneic Transplantation: A Single-Center Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1131-1136.	2.0	2
22	Impact of neutropenia evaluated in terms of the Dâ€ndex on invasive fungal disease while on empiric or preemptive antifungal treatment strategy in the early phase after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13409.	0.7	4
23	Pre-Hematopoietic Stem Cell Transplantation Lung Computed Tomography as an Alternative to the Pulmonary Function Test during the COVID-19 Pandemic. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2318-2322.	2.0	2
24	The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2393-2404.	0.8	5
25	Impact of blood pressure early after allogeneic hematopoietic cell transplantation on clinical outcomes. <i>Annals of Hematology</i> , 2020, 99, 1369-1376.	0.8	1
26	Impact of graftâ€versusâ€host disease and graftâ€versusâ€leukemia effect based on minimal residual disease in Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. <i>British Journal of Haematology</i> , 2020, 190, 84-92.	1.2	13
27	Autologous Hematopoietic Recovery after Unrelated Umbilical Cord Blood Transplantation with Myeloablative Conditioning for Acute Myelogenous Leukemia. <i>Internal Medicine</i> , 2020, 59, 2409-2414.	0.3	2
28	Association between the kinetics of cytomegalovirus reactivation evaluated in terms of the area under the curve of cytomegalovirus antigenemia and invasive mold infection during the postâ€engraftment phase after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13387.	0.7	6
29	Impact of the patient's body weight on the efficacy and adverse events of valganciclovir for cytomegalovirus reactivation after hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13270.	0.7	3
30	Prospective validation of the L-index reflecting both the intensity and duration of lymphopenia and its detailed evaluation using a lymphocyte subset analysis after allogeneic hematopoietic stem cell transplantation. <i>Transplant Immunology</i> , 2020, 58, 101262.	0.6	5
31	Detection of T315I using digital polymerase chain reaction in allogeneic transplant recipients with Ph-positive acute lymphoblastic anemia in the dasatinib era. <i>Experimental Hematology</i> , 2020, 81, 60-67.	0.2	8
32	Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. <i>Bone Marrow Transplantation</i> , 2020, 55, 1317-1325.	1.3	14
33	Myeloablative Vs Reduced-Intensity Conditioning for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Among Patients over 50 Years Old Who Achieved Negative Minimal Residual Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S162-S163.	2.0	0
34	Increased CD83 expression of CD34-positive monocytes in donors during peripheral blood stem cell mobilization in humans. <i>Scientific Reports</i> , 2019, 9, 16499.	1.6	5
35	Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. <i>Cancer Science</i> , 2019, 110, 3255-3266.	1.7	32
36	Updated Clinical Outcomes of Hematopoietic Stem Cell Transplantation Using Myeloablative Total Body Irradiation with Ovarian Shielding to Preserve Fertility. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2461-2467.	2.0	8

#	ARTICLE	IF	CITATIONS
37	Prophylactic Use of Tyrosine Kinase Inhibitors in Patients with Negative Results for Minimal Residual Disease after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S120-S121.	2.0	0
38	Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT. <i>Blood Advances</i> , 2019, 3, 3287-3296.	2.5	2
39	Associations between febrile neutropenia-related parameters and the risk of acute GVHD or non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 707-716.	1.3	3
40	Haploidentical transplantation using low-dose alemtuzumab: Comparison with haploidentical transplantation using low-dose thymoglobulin. <i>European Journal of Haematology</i> , 2019, 102, 256-264.	1.1	14
41	Negative impact of chronic graft-versus-host disease and glucocorticoid on the recovery of physical function after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 994-1003.	1.3	25
42	Impact of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect Based on Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 4522-4522.	0.6	0
43	Refractory Graft-Versus-Host Disease-Free, Relapse-Free Survival as an Accurate and Easy-to-Calculate Endpoint to Assess the Long-Term Transplant Success. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1521-1526.	2.0	10
44	Association between Activated Partial Thromboplastin Time and the Amount of Infused Heparin at Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1367-1371.	2.0	1
45	Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome. <i>Hematological Oncology</i> , 2018, 36, 276-284.	0.8	23
46	Pseudo-autologous stem cell transplantation for donor-derived mantle cell lymphoma 12 years after allogeneic transplantation. <i>International Journal of Hematology</i> , 2018, 107, 117-121.	0.7	4
47	Impact of estimated glomerular filtration rate based on plasma cystatin C and serum creatinine levels before allogeneic hematopoietic cell transplantation. <i>Hematology</i> , 2018, 23, 271-276.	0.7	4
48	Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin. <i>Annals of Hematology</i> , 2018, 97, 169-179.	0.8	5
49	Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography. <i>Infectious Diseases</i> , 2018, 50, 280-288.	1.4	3
50	Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan. <i>International Journal of Hematology</i> , 2018, 108, 423-431.	0.7	3
51	Outcome of gastrointestinal graft-versus-host disease according to the treatment response. <i>Annals of Hematology</i> , 2018, 97, 1951-1960.	0.8	9
52	Additional Cytogenetic Abnormalities with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia on Allogeneic Stem Cell Transplantation in the Tyrosine Kinase Inhibitor Era. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2009-2016.	2.0	19
53	The Expression of CD83 Would be Increased in CD34-Positive Monocytes Detected in Peripheral Blood Mobilized By G-CSF in Humans. <i>Blood</i> , 2018, 132, 2063-2063.	0.6	0
54	Increased Mac 2-Binding Protein Glycan Isomer (M2BPGi) Would Predict Late Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 2125-2125.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Clinical characteristics and predictive factors for mortality in coryneform bacteria bloodstream infection in hematological patients. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 148-153.	0.8	14
56	Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. <i>International Journal of Hematology</i> , 2017, 105, 578-586.	0.7	25
57	Comparison of levofloxacin and garenoxacin for antibacterial prophylaxis during neutropenia. <i>International Journal of Hematology</i> , 2017, 105, 835-840.	0.7	1
58	Acyclovir-resistant herpes simplex virus 1 infection early after allogeneic hematopoietic stem cell transplantation with T-cell depletion. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 485-487.	0.8	13
59	HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG): Tj ETQq1 1 0.784314 rgBT / Overlock 10	0.7	12
60	A Unique T-Cell Receptor Amino Acid Sequence Selected by Human T-Cell Lymphotropic Virus Type 1 Tax <sub>301-309</sub> -Specific Cytotoxic T Cells in HLA-A24:02-Positive Asymptomatic Carriers and Adult T-Cell Leukemia/Lymphoma Patients. <i>Journal of Virology</i> , 2017, 91, .	1.5	8
61	Clinical significance of repeat blood cultures during febrile neutropenia in adult acute myeloid leukaemia patients undergoing intensive chemotherapy. <i>Infectious Diseases</i> , 2017, 49, 748-757.	1.4	19
62	Positive Cytotoxic Crossmatch Predicts Delayed Neutrophil Engraftment in Allogeneic Hematopoietic Cell Transplantation from HLA-Mismatched Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1895-1902.	2.0	2
63	Assessment of the ovarian reserve with anti-MÃ¼llerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding. <i>International Journal of Hematology</i> , 2016, 104, 110-116.	0.7	13
64	Significance of a positive <i><sc>C</sc>lostridium difficile</i> toxin test after hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2016, 30, 703-708.	0.8	12
65	Risk Factors and Impact of Secondary Failure of Platelet Recovery After Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1678-1683.	2.0	33
66	Impact of D-index and L-index on pulmonary infection in induction chemotherapy for acute lymphoblastic leukemia and lymphoblastic lymphoma. <i>Hematology</i> , 2016, 21, 19-25.	0.7	7
67	High Incidence of Afebrile Bloodstream Infection Detected by Surveillance Blood Culture in Patients on Corticosteroid Therapy after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 371-377.	2.0	19
68	Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, l-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL. <i>Annals of Hematology</i> , 2016, 95, 87-92.	0.8	9
69	Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma. <i>Journal of Chemotherapy</i> , 2015, 27, 99-105.	0.7	9
70	Risk factors for pre- and post-engraftment bloodstream infections after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2015, 17, 56-65.	0.7	60
71	Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2015, 102, 230-237.	0.7	29
72	Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning. <i>Hematology</i> , 2015, 20, 410-415.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients. <i>Hematology</i> , 2015, 20, 77-82.	0.7	12
74	Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseases. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 951-961.	1.3	5
75	Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2015, 101, 497-504.	0.7	9
76	False-positive <i>Aspergillus galactomannan</i> and its kinetics in allogeneic hematopoietic stem cell transplantation. <i>Journal of Infection</i> , 2015, 70, 520-540.	1.7	17
77	A retrospective analysis of computed tomography findings in patients with pulmonary complications after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Radiology</i> , 2015, 84, 2663-2670.	1.2	6
78	Persistence of recipientâ€derived as well as donorâ€derived clones of cytomegalovirus pp65â€specific cytotoxic T cells long after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2014, 16, 930-940.	0.7	4
79	Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 553-560.	1.3	8
80	Allotype analysis to determine the origin of cytomegalovirus immunoglobulinâ€G after allogeneic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2014, 16, 904-913.	0.7	1
81	A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia. <i>International Journal of Hematology</i> , 2014, 99, 311-317.	0.7	14
82	Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. <i>Journal of Infection</i> , 2014, 69, 13-25.	1.7	57
83	Universal cytotoxic activity of a HTLV-1 Tax-specific T cell clone from an HLA-A*24:02+ patient with adult T-cell leukemia against a variety of HTLV-I-infected T-cells. <i>Immunology Letters</i> , 2014, 158, 120-125.	1.1	11
84	Successful treatment of the TEMPI syndrome with pomalidomide plus dexamethasone followed by autologous stem cell transplantation. <i>Acta Haematologica</i> , 0, , .	0.7	4